RU2002103219A - Derivatives of mutilins and their use as antibacterial agents - Google Patents

Derivatives of mutilins and their use as antibacterial agents

Info

Publication number
RU2002103219A
RU2002103219A RU2002103219/04A RU2002103219A RU2002103219A RU 2002103219 A RU2002103219 A RU 2002103219A RU 2002103219/04 A RU2002103219/04 A RU 2002103219/04A RU 2002103219 A RU2002103219 A RU 2002103219A RU 2002103219 A RU2002103219 A RU 2002103219A
Authority
RU
Russia
Prior art keywords
formula
alkyl
hydrogen atom
compound
hydrogen
Prior art date
Application number
RU2002103219/04A
Other languages
Russian (ru)
Other versions
RU2276135C2 (en
Inventor
Герд Ашер
Хайнц БЕРНЕР
Иоганнес ХИЛЬДЕБРАНДТ
Original Assignee
Биохеми Гезельшафт М.Б.Х.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918037.4A external-priority patent/GB9918037D0/en
Application filed by Биохеми Гезельшафт М.Б.Х. filed Critical Биохеми Гезельшафт М.Б.Х.
Publication of RU2002103219A publication Critical patent/RU2002103219A/en
Application granted granted Critical
Publication of RU2276135C2 publication Critical patent/RU2276135C2/en

Links

Claims (14)

1. Соединение формулы1. The compound of the formula
Figure 00000001
Figure 00000001
в которой R обозначает водородный атом или алкил;in which R represents a hydrogen atom or alkyl; R1 обозначает группу формулыR 1 represents a group of the formula
Figure 00000002
Figure 00000002
в которой Х обозначает атом серы или кислорода, NR10, где R10 обозначает водородный атом или алкил, или N+(R’10)2, где R'10 обозначает алкил в присутствии соответствующего аниона;wherein X is a sulfur or oxygen atom, NR 10 where R 10 is hydrogen or alkyl, or N + (R '10) 2 wherein R' 10 is alkyl in the presence of an appropriate anion; R9 обозначает аминогруппу, алкил, арил, гетероциклил или меркаптогруппу, а если Х обозначает атом кислорода, дополнительным значением R9 является водородный атом;R 9 is an amino group, alkyl, aryl, heterocyclyl or mercapto group, and if X is an oxygen atom, the additional value of R 9 is a hydrogen atom; R2 обозначает фенилен;R 2 is phenylene; R4 обозначает водородный атом или алкил;R 4 represents a hydrogen atom or alkyl; R5 обозначает водородный атом или алкил;R 5 represents a hydrogen atom or alkyl; R3, R’3, R6, R7 и R8 каждый независимо друг от друга обозначает атом водорода или дейтерия;R 3 , R ' 3 , R 6 , R 7 and R 8 each independently from each other represents a hydrogen atom or deuterium; или R и R2 совместно с азотным атомом, с которым они связаны, образуют неароматический гетероциклен, a R1 обозначает группу формулыor R and R 2 together with the nitrogen atom to which they are attached form a non-aromatic heterocycle, and R 1 represents a group of the formula
Figure 00000003
Figure 00000003
в которой Х и R9 имеют значения, указанные выше.in which X and R 9 have the meanings indicated above.
2. Соединение формулы I по п.1, в которой R обозначает водородный атом; R1 обозначает группу формулы2. The compound of formula I according to claim 1, in which R represents a hydrogen atom; R 1 represents a group of the formula
Figure 00000004
Figure 00000004
в которой Х обозначает атом серы или кислорода, NR10, где R10 обозначает водородный атом или алкил, или N+(R’10)2, где R’10 обозначает алкил в присутствии соответствующего аниона;wherein X is a sulfur or oxygen atom, NR 10 where R 10 is hydrogen or alkyl, or N + (R '10) 2 wherein R' 10 is alkyl in the presence of an appropriate anion; R9 обозначает аминогруппу, алкил, гетероциклил или меркаптогруппу,R 9 represents an amino group, an alkyl, heterocyclyl or mercapto group, а если Х обозначает атом кислорода, дополнительным значением R9 является водородный атом;and if X represents an oxygen atom, the additional value of R 9 is a hydrogen atom; R2 обозначает фенилен; R4 обозначает водородный атом или алкил; R5 обозначает водородный атом; R3 и R’3 обозначают атомы водорода; R6, R7 и R8 обозначают атомы водорода или дейтерия; или R и R2 совместно с азотным атомом, с которым они связаны, образуют неароматический гетероциклен, а R1 обозначает группу формулыR 2 is phenylene; R 4 represents a hydrogen atom or alkyl; R 5 represents a hydrogen atom; R 3 and R ′ 3 are hydrogen atoms; R 6 , R 7 and R 8 are hydrogen or deuterium atoms; or R and R 2 together with the nitrogen atom to which they are attached form a non-aromatic heterocycle, and R 1 represents a group of the formula
Figure 00000005
Figure 00000005
в которой Х обозначает кислородный атом;in which X represents an oxygen atom; R9 обозначает алкил.R 9 is alkyl.
3. Соединение по п.1, которое отвечает формуле3. The compound according to claim 1, which corresponds to the formula
Figure 00000006
Figure 00000006
в которой R1S, обозначает группу формулыin which R 1S , denotes a group of the formula
Figure 00000007
Figure 00000007
в которой R6S обозначает атом водорода или дейтерия;in which R 6S represents a hydrogen atom or deuterium; R2S обозначает водородный атом, метил или трет-бутил;R 2S represents a hydrogen atom, methyl or tert-butyl; R7S обозначает водородный атом или метил;R 7S represents a hydrogen atom or methyl; R3S, R4S и R5S обозначают атомы водорода или дейтерия.R 3S , R 4S and R 5S are hydrogen or deuterium atoms.
4. Соединение по п.1, которое отвечает формуле4. The compound according to claim 1, which corresponds to the formula
Figure 00000008
Figure 00000008
в которой R3SS, R4SS и R5SS обозначают атомы водорода или дейтерия.in which R 3SS , R 4SS and R 5SS are hydrogen or deuterium atoms.
5. Соединение по п.1, которое выбирают из ряда, включающего5. The compound according to claim 1, which is selected from the range including 14-O-(3-(пиперидин-2-илкарбониламино)фенилсульфанилацетил)мутилин;14-O- (3- (piperidin-2-ylcarbonylamino) phenylsulfanylacetyl) mutiline; 14-O-(3-(пиперидин-2-илкарбониламино)фенилсульфанилацетил)-2,2,4-тридейтеромутилин;14-O- (3- (piperidin-2-ylcarbonylamino) phenylsulfanylacetyl) -2,2,4-trideuteromutiline; 14-O-(3-(пиперидин-2-илкарбониламино)-2,5-диметилфенилтиометилкарбонил)мутилин;14-O- (3- (piperidin-2-ylcarbonylamino) -2,5-dimethylphenylthiomethylcarbonyl) mutiline; 14-O-(3-(пиперидин-2-илкарбониламино)-2,5-диметилфенилтиометилкарбонил)-2,2,4-тридейтеромутилин;14-O- (3- (piperidin-2-ylcarbonylamino) -2,5-dimethylphenylthiomethylcarbonyl) -2,2,4-trideuteromutiline; 14-O-(3-(пиперидин-2-илкарбониламино)-5-трет-бутилфенилсульфанилацетил)мутилин и14-O- (3- (piperidin-2-ylcarbonylamino) -5-tert-butylphenylsulfanylacetyl) mutiline and 14-O-(3-(пиперидин-2-илкарбониламино)-5-трет-бутилфенилсульфанилацетил)-2,2,4-тридейтеромутилин.14-O- (3- (piperidin-2-ylcarbonylamino) -5-tert-butylphenylsulfanylacetyl) -2,2,4-trideuteromutiline. 6. Соединение по любому из пп.1-5 в форме соли или в форме соли и в форме сольвата, или в форме сольвата.6. The compound according to any one of claims 1 to 5 in the form of a salt or in the form of a salt and in the form of a solvate, or in the form of a solvate. 7. Соединение по любому из пп.1-6 для применения в качестве фармацевтического средства.7. The compound according to any one of claims 1 to 6 for use as a pharmaceutical. 8. Соединение по п.7 для применения в качестве антимикробного средства.8. The compound according to claim 7 for use as an antimicrobial agent. 9. Соединение формулы I для применения при приготовлении лекарственного средства для лечения обусловленных микробами заболеваний.9. The compound of formula I for use in the preparation of a medicament for the treatment of microbial diseases. 10. Соединение формулы I для применения при приготовлении лекарственного средства для лечения обусловленных микробами заболеваний, вызванных бактериями, включая штаммы, резистентные к пенициллину или множеству лекарств, ванкомицин-резистентные штаммы и метициллин-резистентные штаммы.10. The compound of formula I for use in the preparation of a medicament for the treatment of microbial diseases caused by bacteria, including penicillin or multidrug resistant strains, vancomycin-resistant strains and methicillin-resistant strains. 11. Способ лечения обусловленных микробами заболеваний, который включает введение в организм субъекта, нуждающегося в таком лечении, эффективного количества соединения формулы I.11. A method of treating diseases caused by microbes, which includes the introduction into the body of a subject in need of such treatment, an effective amount of a compound of formula I. 12. Фармацевтическая композиция, включающая соединение формулы I в свободной форме или в форме фармацевтически приемлемой соли в сочетании с по меньшей мере одним фармацевтически приемлемым носителем или разбавителем.12. A pharmaceutical composition comprising a compound of formula I in free form or in the form of a pharmaceutically acceptable salt in combination with at least one pharmaceutically acceptable carrier or diluent. 13. Соединение формулы I для применения в качестве ветеринарного средства.13. The compound of formula I for use as a veterinary agent. 14. Соединение формулы I для приготовления ветеринарной композиции, которая может быть использована в качестве ветеринарного средства.14. The compound of formula I for the preparation of a veterinary composition, which can be used as a veterinary medicine.
RU2002103219/04A 1999-07-30 2000-07-28 Derivatives of mutilins and their using as antibacterial agents RU2276135C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918037.4A GB9918037D0 (en) 1999-07-30 1999-07-30 Organic compounds
GB9918037.4 1999-07-30

Publications (2)

Publication Number Publication Date
RU2002103219A true RU2002103219A (en) 2003-09-20
RU2276135C2 RU2276135C2 (en) 2006-05-10

Family

ID=10858319

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002103219/04A RU2276135C2 (en) 1999-07-30 2000-07-28 Derivatives of mutilins and their using as antibacterial agents

Country Status (34)

Country Link
US (2) US6784193B1 (en)
EP (2) EP1666466B1 (en)
JP (2) JP4711580B2 (en)
KR (2) KR100878074B1 (en)
CN (2) CN1182116C (en)
AR (1) AR024964A1 (en)
AT (2) ATE319686T1 (en)
AU (1) AU757799B2 (en)
BR (2) BR0012880A (en)
CA (1) CA2380980C (en)
CO (1) CO5180568A1 (en)
CZ (1) CZ2002345A3 (en)
DE (2) DE60045321D1 (en)
DK (1) DK1198454T3 (en)
EC (1) ECSP003591A (en)
ES (2) ES2259610T3 (en)
GB (1) GB9918037D0 (en)
HK (2) HK1047087B (en)
HU (1) HU229483B1 (en)
IL (2) IL147072A0 (en)
MX (1) MXPA02001091A (en)
MY (1) MY133731A (en)
NO (1) NO322562B1 (en)
NZ (1) NZ516711A (en)
PE (1) PE20010544A1 (en)
PL (1) PL205609B1 (en)
PT (1) PT1198454E (en)
RU (1) RU2276135C2 (en)
SI (1) SI1198454T1 (en)
SK (1) SK1272002A3 (en)
TR (1) TR200103764T2 (en)
TW (1) TWI281468B (en)
WO (1) WO2001009095A1 (en)
ZA (1) ZA200200695B (en)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020676A1 (en) * 2000-09-13 2002-08-27 Biochemie Gmbh MUTILIN COMPOUNDS AS ANTIBACTERIAL
GB0207495D0 (en) 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
GB0209262D0 (en) * 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
RU2005105576A (en) * 2002-07-24 2005-10-10 Сандоз АГ (CH) Pleuromutilin derivatives as antimicrobial agents
WO2005023257A1 (en) * 2003-09-03 2005-03-17 Glaxo Group Limited Novel process, salts, compositions and use
GB0504314D0 (en) * 2005-03-02 2005-04-06 Glaxo Group Ltd Novel polymorph
JP2008534444A (en) * 2005-03-10 2008-08-28 スミスクライン・ビーチャム・コーポレイション New method
GB0513058D0 (en) * 2005-06-27 2005-08-03 Sandoz Ag Organic compounds
GB0515995D0 (en) * 2005-08-03 2005-09-07 Sandoz Ag Organic compounds
WO2007037518A1 (en) * 2005-09-29 2007-04-05 Dainippon Sumitomo Pharma Co., Ltd. Mutilin derivative and pharmaceutical composition containing the same
EP1808431A1 (en) * 2006-01-16 2007-07-18 Nabriva Therapeutics Forschungs GmbH Mutilin derivatives and their use as pharmaceutical
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
CA2647598A1 (en) * 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
CN102442970A (en) * 2006-05-31 2012-05-09 雅培制药有限公司 Novel compounds as cannabinoid receptor ligands and uses thereof
WO2007143507A2 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
EP1908750A1 (en) 2006-10-05 2008-04-09 Nabriva Therapeutics Forschungs GmbH Process for the preparation of pleuromutilins
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
US7875640B2 (en) 2007-03-28 2011-01-25 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8501794B2 (en) * 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7872033B2 (en) * 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2160393A1 (en) * 2007-05-18 2010-03-10 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US8222407B2 (en) * 2007-05-24 2012-07-17 Kyorin Pharmaceutical Co., Ltd. Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
EP2014640A1 (en) 2007-07-13 2009-01-14 Nabriva Therapeutics AG Pleuromutilin derivatives
EP2014645A1 (en) 2007-07-13 2009-01-14 Nabriva Therapeutics AG Pleuromutilin derivatives and their use as antimicrobials
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
CA2716857A1 (en) * 2008-03-11 2009-09-17 Teodozyi Kolasa Novel compounds as cannabinoid receptor ligands
CN103224487A (en) 2008-04-01 2013-07-31 雅培股份有限两合公司 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
MX2011001370A (en) * 2008-08-05 2011-03-15 Abbott Lab Compounds useful as inhibitors of protein kinases.
MX2011001755A (en) * 2008-08-15 2011-03-24 Abbott Lab Imine derivatives as cannabinoid receptor ligands.
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
BRPI0919135A2 (en) * 2008-09-16 2015-12-08 Abbott Lab novel compounds as cannabinoid receptor ligands.
MX2011004081A (en) * 2008-10-17 2011-05-31 Abbott Lab Trpv1 antagonists.
JP2012505908A (en) * 2008-10-17 2012-03-08 アボット・ラボラトリーズ TRPV1 antagonist
WO2010056855A1 (en) * 2008-11-13 2010-05-20 Teva Pharmaceutical Industries Ltd. Preparation of retapamulin via its pleuromutilin-thiol precursor
UA108193C2 (en) 2008-12-04 2015-04-10 APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
ME02642B (en) 2008-12-05 2017-06-20 Abbvie Inc Sulfonamide derivatives as bcl- 2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) * 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PA8854001A1 (en) 2008-12-16 2010-07-27 Abbott Lab NEW COMPOUNDS AS CANABINOID RECEIVERS LIGANDS
ES2536090T3 (en) 2009-01-19 2015-05-20 Abbvie Inc. Agents inducing apoptosis for the treatment of cancer and immune and autoimmune diseases
BRPI1006115A8 (en) * 2009-01-19 2017-09-26 Abbott Lab "APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES".
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (en) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
TWI519530B (en) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 Carboxamide compounds and their use as calpain inhibitors
US8236822B2 (en) * 2009-03-27 2012-08-07 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2411370B1 (en) * 2009-03-27 2015-04-22 AbbVie Inc. Compounds as cannabinoid receptor ligands
EP2411382A1 (en) * 2009-03-27 2012-02-01 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
PL2435432T6 (en) 2009-05-26 2024-02-12 Abbvie Ireland Unlimited Company Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138828A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Potassium channel modulators
WO2011053740A1 (en) 2009-10-28 2011-05-05 Belkin International, Inc. Portable multi-media communication device protective carrier and method of manufacture therefor
WO2011066168A1 (en) 2009-11-25 2011-06-03 Abbott Laboratories Potassium channel modulators
TW201130855A (en) * 2009-12-16 2011-09-16 Abbott Lab Prodrug compounds useful as cannabinoid ligands
KR20130040834A (en) * 2010-03-25 2013-04-24 아비에 인코포레이티드 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (en) 2010-05-26 2016-02-11 艾伯維有限公司 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586596B2 (en) 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands
KR20130097748A (en) 2010-08-10 2013-09-03 아비에 인코포레이티드 Novel trpv3 modulators
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012041814A1 (en) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
RU2598345C2 (en) 2010-10-29 2016-09-20 Эббви Инк. Solid dispersions containing agents causing apoptosis
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012067963A1 (en) 2010-11-15 2012-05-24 Abbott Laboratories Nampt inhibitors
CN103313968A (en) 2010-11-15 2013-09-18 Abbvie公司 Nampt and rock inhibitors
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
US8609674B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
AU2011332043C1 (en) 2010-11-23 2016-11-10 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
UY33966A (en) 2011-03-25 2012-10-31 Abbott Lab VANILLOID POTENTIAL TRANSITORY RECEIVER ANTAGONISTS 1 (TRPV1)
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012158399A1 (en) 2011-05-13 2012-11-22 Abbott Laboratories Condensed 2 - carbamoylpyridazinones as potassium channel modulators
CA2844275A1 (en) 2011-08-05 2013-02-14 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
TWI571466B (en) 2011-10-14 2017-02-21 艾伯維有限公司 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI561521B (en) 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2014530911A (en) 2011-10-24 2014-11-20 アッヴィ・インコーポレイテッド Methanol derivatives as TRPV3 modulators
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
CN103204787B (en) * 2012-01-17 2014-10-01 北京艾百诺科技有限公司 Mulin acetate comprising substituted squaric acid, and application thereof
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
EP2838881B1 (en) 2012-04-20 2018-08-08 AbbVie Inc. Isoindolone derivatives
WO2013170113A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
PE20150224A1 (en) 2012-05-11 2015-03-08 Abbvie Inc NAMPT INHIBITORS
AR091023A1 (en) 2012-05-11 2014-12-30 Abbvie Inc NAMPT INHIBITORS
JP2015516437A (en) 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Thiazole carboxamide derivatives used as NAMPT inhibitors
US20130317054A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US20130317055A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
BR112014031068A2 (en) 2012-06-12 2017-06-27 Abbvie Inc pyridinone and pyridazinone derivatives
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103626693B (en) * 2012-08-28 2016-09-14 中国科学院上海药物研究所 One class pleuromutilin derivative, its pharmaceutical composition and synthetic method thereof and purposes
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
PE20150777A1 (en) 2012-09-14 2015-06-20 AbbVie Deutschland GmbH and Co KG TRICYCLIC DERIVATIVES OF QUINOLINES AND QUINOXALINES
WO2014160017A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
CN105026393A (en) 2013-03-13 2015-11-04 艾伯维公司 Cdk9 kinase inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2014151444A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
EP2970229B1 (en) 2013-03-14 2017-02-08 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
CN105246890A (en) 2013-03-14 2016-01-13 艾伯维公司 Pyrrolo[2, 3-b]pyridine cdk9 kinase inhibitors
EP2970258B1 (en) 2013-03-14 2018-04-18 AbbVie Deutschland GmbH & Co KG Novel inhibitor compounds of phosphodiesterase type 10a
CN105189512A (en) 2013-03-14 2015-12-23 艾伯维公司 Pyrrolopyrimindine CDK9 kinase inhibitors
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CN105992764A (en) 2013-10-17 2016-10-05 艾伯维德国有限责任两合公司 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
AU2014336154A1 (en) 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015091931A1 (en) 2013-12-20 2015-06-25 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
US9328112B2 (en) 2014-02-06 2016-05-03 Abbvie Inc. Tetracyclic CDK9 kinase inhibitors
US9527856B2 (en) 2014-05-15 2016-12-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US20180243298A1 (en) 2015-04-02 2018-08-30 Abbvie Inc. Trpv3 modulators
EP3636651A1 (en) 2015-11-25 2020-04-15 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
CN109153686B (en) 2016-05-07 2021-04-30 上海复尚慧创医药研究有限公司 Protein kinase inhibitor
CN106565564A (en) * 2016-09-30 2017-04-19 华南农业大学 Pleuromutilin derivative with 2-amino phenyl mercaptan side chain and preparing method and application of pleuromutilin derivative
WO2018058534A1 (en) * 2016-09-30 2018-04-05 华南农业大学 Pleuromutilin derivative having 2-amino phenyl mercaptan side chain, preparation method therefor, and uses thereof
WO2018095432A1 (en) 2016-11-28 2018-05-31 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase
TWI762573B (en) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 Purification of pleuromutilin
WO2018175449A1 (en) 2017-03-21 2018-09-27 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
SI3612531T1 (en) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
CN107417586A (en) * 2017-06-21 2017-12-01 华南农业大学 A kind of pleuromulins antibiotic and its preparation method and application
CN109384698B (en) * 2017-08-04 2022-07-08 保定加合精细化工有限公司 Preparation method of diterpene antibiotic for livestock and poultry
AU2019233204B2 (en) 2018-03-14 2022-02-03 Fochon Biosciences, Ltd. Substituted (2-azabicyclo (3.1.0) hexan-2-yl) pyrazolo (1, 5-a) pyrimidine and imidazo (1, 2-b) pyridazine compounds as TRK kinases inhibitors
US11485707B2 (en) 2018-03-23 2022-11-01 Fochon Pharmaceuticals, Ltd. Deuterated compounds as rock inhibitors
CN109666009B (en) * 2018-11-02 2023-02-03 华南农业大学 Preparation method and application of pleuromutilin derivative by taking 2-aminobenzenethiol as connecting group
CN110372615B (en) * 2019-07-08 2023-02-03 华南农业大学 Pleuromutilin derivative with 2-aminobenzenethiol and 1,2, 3-triazole side chain as well as preparation and application thereof
CN111170911A (en) * 2019-09-29 2020-05-19 安帝康(无锡)生物科技有限公司 Pleuromutilin compounds for treating bacterial infectious diseases
CN110818648B (en) * 2019-12-05 2021-03-16 华南农业大学 Pleuromutilin derivative with triazole side chain as well as preparation method and application thereof
CN113666883B (en) * 2021-07-23 2023-06-16 华南理工大学 Method for synthesizing 4-vinyl isoxazole derivative
CN114940671A (en) * 2022-05-10 2022-08-26 华南农业大学 Pleuromutilin derivative with 4-aminobenzenethiol side chain as well as preparation method and application thereof
CN115850137B (en) * 2022-11-12 2024-04-12 中国农业科学院兰州畜牧与兽药研究所 Pleuromutilin derivative compound and preparation method and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789629A (en) * 1971-10-05 1973-04-03 Sandoz Sa NEW DERIVATIVES OF PLEUROMUTILINE, THEIR PREPARATION AND THERAPEUTIC APPLICATION
US4107164A (en) 1971-10-05 1978-08-15 Sandoz Ltd. Certain pleuromulilin ester derivatives
JPS54160358A (en) * 1978-06-06 1979-12-19 Sandoz Ag Improvement for organic compound
ZA80175B (en) * 1979-01-12 1981-08-26 Sandoz Ltd New pleuromutilin derivatives, their production and use
DE2966635D1 (en) 1979-01-12 1984-03-08 Sandoz Ag New pleuromutilin derivatives, their production and pharmaceutical compositions containing them
DE3560511D1 (en) * 1984-02-17 1987-10-01 Sandoz Ag Pleuromutilin derivatives, process for their preparation and their use
HU208115B (en) * 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
UY25225A1 (en) * 1997-10-29 2000-12-29 Smithkline Beecham Plc PLEUROMUTILINE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS
WO2000027790A1 (en) * 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Mutilin compounds
PE20020676A1 (en) * 2000-09-13 2002-08-27 Biochemie Gmbh MUTILIN COMPOUNDS AS ANTIBACTERIAL

Similar Documents

Publication Publication Date Title
RU2002103219A (en) Derivatives of mutilins and their use as antibacterial agents
JP2003506354A5 (en)
DK0524781T3 (en) Therapeutic amides
PE20010544A1 (en) MUTILIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
RU2003103101A (en) PLEUROMUTILINE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY
DE69330282D1 (en) CHINOLON AND ACRIDINONE DERIVATIVES FOR TREATING URININE CONTINENCE
RU95110762A (en) Derivatives of 5-hydrazine quinolone, composition for treatment or prophylaxis of infection diseases, method for treatment or prophylaxis
AR039475A1 (en) 6-ALQUILIDEN-PENEMS TRICICLICOS AS BETA-LACTAMASA INHIBITORS
RU2003130070A (en) BIGUANID DERIVATIVES
ATE161006T1 (en) ALCOHOL AS A POTASSIUM CHANNEL OPENER AND FOR THE TREATMENT OF URINARY INCONTINENCE
KR890003378A (en) Naphthyridine Compounds Having Antimicrobial Activity Against Anaerobic Bacteria
KR890008136A (en) Antimicrobial 9-Deoxo-9a-allyl and propargyl-9a-aza-9a-homoerythromycin A derivatives
TR200400220T4 (en) As antagonists of bradykinin, 1,4-dihydropyridine compounds substituted with 5-membered heteroaryl.
DK1209166T3 (en) Newly known A-500 359 derivatives
ES2084120T3 (en) MEDICINES TO PREVENT AND TREAT DISEASES OF THE CIRCULATORY SYSTEM CONTAINING SPIRO-3-HETEROAZOLIDINE COMPOUNDS.
RU94042230A (en) 1,3,4-oxadiazole-2-(3h)-one derivatives, preparation and use thereof in therapy
PT1175429E (en) HALO 9-DEOXO-9A-AZA-9A-HOMOERITHROMYCIN A HALO DERIVATIVES
CN102171185A (en) Methionine analogs and methods of using same
EP0210815A3 (en) 6-beta-(alpha-etherified oxyimino)-acylamino penicillanic-acid derivatives, their preparation and use
ES2949216T3 (en) Nitrogen-containing bicyclic compounds
RU2008128365A (en) DIPHENYL UREA DERIVATIVES
RU94033470A (en) Cyclohexane derivatives, pharmcomposition based thereon, and method of treatment
RU95108539A (en) Derivatives of peneme, their production and comprising them pharmaceutical composition
ES8504816A1 (en) Cephalosporin antibiotics.
KR890009930A (en) (1R, 5S, 6S) -2-substituted thio-6-[(R) -1-hydroxyethyl] -1-methyl-carbapenem-3-carboxylic acid derivative